Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2018

13.11.2017 | Colorectal Cancer

Organ Preservation in Rectal Cancer After Chemoradiation: Should We Extend the Observation Period in Patients with a Clinical Near-Complete Response?

verfasst von: Britt J. P. Hupkens, MD, Monique Maas, MD, PhD, Milou H. Martens, MD, PhD, Marit E. van der Sande, MD, Doenja M. J. Lambregts, MD, PhD, Stéphanie O. Breukink, MD, PhD, Jarno Melenhorst, MD, PhD, Janneke B. Houwers, MD, Christiaan Hoff, MD, PhD, Meindert N. Sosef, MD, PhD, Jeroen W. A. Leijtens, MD, Maaike Berbee, MD, Regina G. H. Beets-Tan, MD, PhD, Geerard L. Beets, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

To assess whether extending the observation period in patients with a near clinical complete response (near cCR) after chemoradiation (CRT) leads to an impaired oncological outcome.

Methods

Patients who had a clinical complete response (cCR) 8–10 weeks after CRT restaging with magnetic resonance imaging and endoscopy were offered a watch-and-wait strategy (W&W1), while patients with a near cCR were offered to undergo local excision or a second restaging 6–12 weeks later. Patients who achieved a cCR at the second restaging were also offered a watch-and-wait strategy (W&W2).

Results

Overall, 102 patients with a cCR at the first restaging immediately entered the W&W1, while the remaining 68 patients had a near cCR: 19 patients underwent transanal endoscopic microsurgery and 49 patients opted for a second restaging. Additionally, 44/49 (90%) patients showed a cCR at the second restaging and entered the W&W2. Patients in the W&W1 group had a 2-year local regrowth-free rate (LRFR) of 84% and 2-year overall survival (OS) of 99%, while patients in the W&W2 group had a 2-year LRFR of 73% and OS of 98% (p > 0.05). Multivariable Cox regression analyses showed that late inclusion was not a significant predictive factor for higher risk of LR or lower non-regrowth disease-free survival.

Conclusions

Overall, 90% of patients with a near cCR 8–10 weeks after CRT will proceed to a cCR 6–12 weeks later; therefore, it seems logical to extend the observation period rather than to proceed to surgery. Although there is a non-significant increase in local regrowth rate in these patients, it does not seem to impact the oncological outcome.
Literatur
1.
Zurück zum Zitat Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11(9):835–44.CrossRefPubMed Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11(9):835–44.CrossRefPubMed
2.
Zurück zum Zitat Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240(4):711–7; discussion 717-8.PubMedPubMedCentral Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240(4):711–7; discussion 717-8.PubMedPubMedCentral
3.
Zurück zum Zitat Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29(35):4633–40.CrossRefPubMed Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29(35):4633–40.CrossRefPubMed
4.
Zurück zum Zitat Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012; 256(6):965–72.CrossRefPubMed Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012; 256(6):965–72.CrossRefPubMed
5.
Zurück zum Zitat Ayloor SR KS, Jayanand SB, et al. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided? Hepatogastroenterology 2013;60(123):410–414. Ayloor SR KS, Jayanand SB, et al. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided? Hepatogastroenterology 2013;60(123):410–414.
6.
Zurück zum Zitat Appelt AL, Ploen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 2015;16(8):919–927.CrossRefPubMed Appelt AL, Ploen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 2015;16(8):919–927.CrossRefPubMed
7.
Zurück zum Zitat Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17(2):174–83.CrossRefPubMed Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17(2):174–83.CrossRefPubMed
9.
Zurück zum Zitat Beets GL, Figueiredo NF, Beets-Tan RG. Management of Rectal Cancer Without Radical Resection. Annu Rev Med 2017;68:169–182.CrossRefPubMed Beets GL, Figueiredo NF, Beets-Tan RG. Management of Rectal Cancer Without Radical Resection. Annu Rev Med 2017;68:169–182.CrossRefPubMed
10.
Zurück zum Zitat Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc 2008; 22(2):352–8.CrossRefPubMed Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc 2008; 22(2):352–8.CrossRefPubMed
11.
Zurück zum Zitat Perez RO, Habr-Gama A, Sao Juliao GP, et al. Transanal endoscopic microsurgery (TEM) following neoadjuvant chemoradiation for rectal cancer: outcomes of salvage resection for local recurrence. Ann Surg Oncol 2016;23(4):1143–8.CrossRefPubMed Perez RO, Habr-Gama A, Sao Juliao GP, et al. Transanal endoscopic microsurgery (TEM) following neoadjuvant chemoradiation for rectal cancer: outcomes of salvage resection for local recurrence. Ann Surg Oncol 2016;23(4):1143–8.CrossRefPubMed
12.
Zurück zum Zitat Perez RO, Habr-Gama A, Sao Juliao GP, et al. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis Colon Rectum 2011; 54(5):545–51.CrossRefPubMed Perez RO, Habr-Gama A, Sao Juliao GP, et al. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis Colon Rectum 2011; 54(5):545–51.CrossRefPubMed
13.
Zurück zum Zitat Coco C, Rizzo G, Mattana C, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc 2013; 27(8):2860–7.CrossRefPubMed Coco C, Rizzo G, Mattana C, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc 2013; 27(8):2860–7.CrossRefPubMed
14.
Zurück zum Zitat Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015; 16(15):1537–46.CrossRefPubMedPubMedCentral Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015; 16(15):1537–46.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013; 100(7):933–9.CrossRefPubMed Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013; 100(7):933–9.CrossRefPubMed
16.
Zurück zum Zitat Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 2015; 22(12):3873–80.CrossRefPubMedPubMedCentral Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 2015; 22(12):3873–80.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat West MA, Dimitrov BD, Moyses HE, et al. Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer—a comparison of magnetic resonance imaging at two time points and histopathological responses. Eur J Surg Oncol 2016; 42(9):1350–8.CrossRefPubMed West MA, Dimitrov BD, Moyses HE, et al. Timing of surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer—a comparison of magnetic resonance imaging at two time points and histopathological responses. Eur J Surg Oncol 2016; 42(9):1350–8.CrossRefPubMed
18.
Zurück zum Zitat Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum 2016;59(4):255–63.CrossRefPubMed Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum 2016;59(4):255–63.CrossRefPubMed
19.
Zurück zum Zitat Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol 2010; 49(3):378–81.CrossRefPubMed Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol 2010; 49(3):378–81.CrossRefPubMed
20.
Zurück zum Zitat Nakagawa WT, Rossi BM, de OFF, et al. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? Ann Surg Oncol 2002;9(6):568–73.CrossRefPubMed Nakagawa WT, Rossi BM, de OFF, et al. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? Ann Surg Oncol 2002;9(6):568–73.CrossRefPubMed
21.
Zurück zum Zitat Lim L, Chao M, Shapiro J, et al. Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. Dis Colon Rectum 2007; 50(12):2032-9.CrossRefPubMed Lim L, Chao M, Shapiro J, et al. Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. Dis Colon Rectum 2007; 50(12):2032-9.CrossRefPubMed
22.
Zurück zum Zitat Habr-Gama A, Lynn PB, Jorge JM, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum 2016; 59(4):264–9.CrossRefPubMed Habr-Gama A, Lynn PB, Jorge JM, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum 2016; 59(4):264–9.CrossRefPubMed
23.
Zurück zum Zitat Habr-Gama A, de Souza PM, Ribeiro U, Jr., et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41(9):1087–96.CrossRefPubMed Habr-Gama A, de Souza PM, Ribeiro U, Jr., et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41(9):1087–96.CrossRefPubMed
24.
Zurück zum Zitat Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016;34:3773–3780.CrossRefPubMed Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016;34:3773–3780.CrossRefPubMed
25.
Zurück zum Zitat Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 2016; 263(3):458–64.CrossRefPubMed Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 2016; 263(3):458–64.CrossRefPubMed
26.
Zurück zum Zitat Creavin B, Ryan E, Martin ST, et al. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer 2017;116(2):169–174.CrossRefPubMed Creavin B, Ryan E, Martin ST, et al. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer 2017;116(2):169–174.CrossRefPubMed
27.
Zurück zum Zitat Huang CM, Huang MY, Tsai HL, et al. An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy. Therap Adv Gastroenterol 2016; 9(5):702-12.CrossRefPubMedPubMedCentral Huang CM, Huang MY, Tsai HL, et al. An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy. Therap Adv Gastroenterol 2016; 9(5):702-12.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015; 16(8):957–66.CrossRefPubMedPubMedCentral Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015; 16(8):957–66.CrossRefPubMedPubMedCentral
Metadaten
Titel
Organ Preservation in Rectal Cancer After Chemoradiation: Should We Extend the Observation Period in Patients with a Clinical Near-Complete Response?
verfasst von
Britt J. P. Hupkens, MD
Monique Maas, MD, PhD
Milou H. Martens, MD, PhD
Marit E. van der Sande, MD
Doenja M. J. Lambregts, MD, PhD
Stéphanie O. Breukink, MD, PhD
Jarno Melenhorst, MD, PhD
Janneke B. Houwers, MD
Christiaan Hoff, MD, PhD
Meindert N. Sosef, MD, PhD
Jeroen W. A. Leijtens, MD
Maaike Berbee, MD
Regina G. H. Beets-Tan, MD, PhD
Geerard L. Beets, MD, PhD
Publikationsdatum
13.11.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6213-8

Weitere Artikel der Ausgabe 1/2018

Annals of Surgical Oncology 1/2018 Zur Ausgabe

Health Services Research and Global Oncology

The Annals of Surgical Oncology: An Oncology Journal for Surgeons

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.